{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:18Z","timestamp":1793228238061,"version":"4.5.0"},"reference-count":323,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hypoxia, a defining hallmark of solid tumors, arises from structurally and functionally abnormal vasculature, rapid cellular proliferation, and impaired perfusion, resulting in chronic and cycling oxygen deprivation within the tumor massThe hypoxic tumor microenvironment orchestrates extensive molecular reprogramming primarily through stabilization and activation of hypoxia-inducible factors (HIF-1\u03b1 and HIF-2\u03b1), which regulate broad transcriptional networks governing metabolism, angiogenesis, stemness, invasion, and immune modulation. Under low oxygen tension, tumor cells shift toward aerobic glycolysis, enhance glutamine utilization, promote lipid synthesis and storage, suppress mitochondrial oxidative phosphorylation, and fine-tune redox balance through coordinated regulation of ROS-generating and antioxidant systems. These adaptations not only sustain proliferation and survival under metabolic stress but also facilitate epithelial\u2013mesenchymal transition, extracellular matrix remodeling, and metastatic dissemination. Beyond malignant cells, hypoxia reprograms stromal compartments\u2014including cancer-associated fibroblasts, endothelial cells, tumor-associated macrophages, and myeloid-derived suppressor cells\u2014thereby establishing a metabolically cooperative, angiogenic, and profoundly immunosuppressive microenvironment. Hypoxia-induced acidosis, lactate accumulation, and HIF-driven cytokine signaling further impair cytotoxic T-cell and NK-cell activity, contributing to immune escape and resistance to radiotherapy, chemotherapy, and immunotherapy. Emerging evidence from single-cell multi-omics, spatial transcriptomics, metabolic imaging, and early-phase clinical trials targeting HIF signaling, angiogenic pathways, and metabolic enzymes has uncovered actionable vulnerabilities in hypoxia-driven malignancies. This review synthesizes the mechanistic foundations of hypoxia-induced metabolic reprogramming, its role in tumor progression and therapeutic resistance, and discusses innovative strategies aimed at exploiting hypoxia-associated metabolic dependencies to advance precision oncology.<\/jats:p>","DOI":"10.3389\/fonc.2026.1771365","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:32:40Z","timestamp":1774935160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Hypoxic microenvironment in cancer: role in metabolic reprogramming"],"prefix":"10.3389","volume":"16","author":[{"given":"Niti","family":"Sureka","sequence":"first","affiliation":[{"name":"Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashi","family":"Maheshwari","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Agravat","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pandit Deendayal Upadhyay (PDU) Medical College","place":["Rajkot, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Singhal","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Vardhman Mahavir Medical College and Safdarjung Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamsuz","family":"Zaman","sequence":"additional","affiliation":[{"name":"Indian Council of Medical Research (ICMR)- Centre for Cancer Pathology","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavika","family":"Rishi","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Child Health and Development Research","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouzia","family":"Siraj","sequence":"additional","affiliation":[{"name":"Indian Council of Medical Research (ICMR)- Centre for Cancer Pathology","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufian","family":"Zaheer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroonima","family":"Misra","sequence":"additional","affiliation":[{"name":"ICMR-National Institute of Child Health and Development Research","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13447","article-title":"Unraveling the intricacies of cancer-associated fibroblasts: a comprehensive review on metabolic reprogramming and tumor microenvironment crosstalk","volume":"132","author":"Ahuja","year":"2024","journal-title":"APMIS"},{"key":"B2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42255-020-00317-z","article-title":"Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism","volume":"3","author":"Elia","year":"2021","journal-title":"Nat Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment","volume":"21","author":"Emami Nejad","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10238-024-01501-1","article-title":"Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies","volume":"24","author":"Ciep\u0142a","year":"2024","journal-title":"Clin Exp Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01180-8","article-title":"Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer","volume":"56","author":"Bae","year":"2024","journal-title":"Exp Mol Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s42003-025-07896-1","article-title":"Redefining the role of hypoxia-inducible factors (HIFs) in oxygen homeostasis","volume":"8","author":"Arias","year":"2025","journal-title":"Commun Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00682-7","article-title":"Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer","volume":"30","author":"Zhang","year":"2025","journal-title":"Cell Mol Biol Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cells14090673","article-title":"The distinct role of HIF-1\u03b1 and HIF-2\u03b1 in hypoxia and angiogenesis","volume":"14","author":"Bakleh","year":"2025","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/imm.70045","article-title":"Molecular mediators of metabolic reprogramming in cancer: mechanisms, regulatory networks, and therapeutic strategies","volume":"177","author":"Ahuja","year":"2026","journal-title":"Immunology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218067","article-title":"Exploiting metabolic vulnerabilities in cancer: From mechanisms to therapeutic opportunities","volume":"634","author":"Xue","year":"2025","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2023.08.014","article-title":"Recent advancements in single-cell metabolic analysis for pharmacological research","volume":"13","author":"Hou","year":"2023","journal-title":"J Pharm Anal"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ph18010075","article-title":"Leveraging single-cell multi-omics to decode tumor microenvironment diversity and therapeutic resistance","volume":"18","author":"Sabit","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155487","article-title":"Targeting hypoxia-driven metabolic reprogramming to constrain tumor progression and metastasis","volume":"21","author":"Miranda-Galvis","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-019-0045-8","article-title":"Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy","volume":"1","author":"Ye","year":"2019","journal-title":"Nat Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1955.55","article-title":"The histological structure of some human lung cancers and the possible implications for radiotherapy","volume":"9","author":"Thomlinson","year":"1955","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7150\/thno.84947","article-title":"Visualizing vasculature and its response to therapy in the tumor microenvironment","volume":"13","author":"Lin","year":"2023","journal-title":"Theranostics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/biom9080339","article-title":"Acute vs. Chronic vs. Cyclic Hypoxia: Their Differential Dynamics, Molecular Mechanisms, and Effects on Tumor Progression","volume":"9","author":"Saxena","year":"2019","journal-title":"Biomolecules"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1331355","article-title":"Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours","volume":"14","author":"Bigos","year":"2024","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-52-620-650","article-title":"Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation","volume":"52","author":"Brown","year":"1979","journal-title":"Br J Radiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13046-020-01733-5","article-title":"Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation","volume":"39","author":"Li","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111798","article-title":"Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more","volume":"141","author":"Hao","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123802","article-title":"Characteristics of the tumor microenvironment that influence immune cell functions: hypoxia, oxidative stress, metabolic alterations","volume":"12","author":"Augustin","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/21541264.2024.2417475","article-title":"Hypoxia-inducible transcription factors: architects of tumorigenesis and targets for anticancer drug discovery","volume":"16","author":"McDermott","year":"2025","journal-title":"Transcription"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/HP.S47968","article-title":"Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism","volume":"2","author":"Yang","year":"2014","journal-title":"Hypoxia (Auckl)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050384","article-title":"Protein hydroxylation by hypoxia-inducible factor (HIF) hydroxylases: unique or ubiquitous","volume":"8","author":"Strowitzki","year":"2019","journal-title":"Cells"},{"key":"B31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.freeradbiomed.2013.01.026","article-title":"Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by \u201cantioxidant\u201d metal chelators: From ferroptosis to stroke","volume":"62","author":"Speer","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10409238.2013.838205","article-title":"Transcriptional regulation by hypoxia inducible factors","volume":"49","author":"Dengler","year":"2014","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e40273","DOI":"10.1097\/MD.0000000000040273","article-title":"Central role of hypoxia-inducible factor-1\u03b1 in metabolic reprogramming of cancer cells: A review","volume":"103","author":"Zhu","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6868","article-title":"Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma","volume":"7","author":"Hu","year":"2016","journal-title":"Oncotarget"},{"key":"B35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10555-019-09799-0","article-title":"The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond","volume":"38","author":"Pastorekova","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"B36","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.23.24.9361-9374.2003","article-title":"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation","volume":"23","author":"Hu","year":"2003","journal-title":"Mol Cell Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00200-09","article-title":"Hypoxia-inducible factor 2 regulates hepatic lipid metabolism","volume":"29","author":"Rankin","year":"2009","journal-title":"Mol Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2025.120007","article-title":"The role of hypoxia-inducible factor-3\u03b1 in human disease","volume":"1872","author":"L\u00f3pez-Mej\u00eda","year":"2025","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.17179\/excli2021-4622","article-title":"Hypoxia-inducible factor (HIF)-3a2 serves as an endothelial cell fate executor during chronic hypoxia","volume":"21","author":"Jaskiewicz","year":"2022","journal-title":"EXCLI J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2010.04.008","article-title":"Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2","volume":"42","author":"Pasanen","year":"2010","journal-title":"Int J Biochem Cell Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-011-0679-5","article-title":"Roles of the human hypoxia-inducible factor (HIF)-3\u03b1 variants in the hypoxia response","volume":"68","author":"Heikkil\u00e4","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C200328200","article-title":"Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus","volume":"277","author":"Makino","year":"2002","journal-title":"J Biol Chem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.02.011","article-title":"Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia","volume":"6","author":"Zhang","year":"2014","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00315.2015","article-title":"Hypoxia-inducible factor 3 biology: complexities and emerging themes","volume":"310","author":"Duan","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02699-3","article-title":"Hypoxia-inducible factor 3\u03b11 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis","volume":"130","author":"Villareal","year":"2024","journal-title":"Br J Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0256","article-title":"HIF-3\u03b1 Promotes metastatic phenotypes in pancreatic cancer by transcriptional regulation of the rhoC-ROCK1 signaling pathway","volume":"16","author":"Zhou","year":"2018","journal-title":"Mol Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700732200","article-title":"Transcriptional up-regulation of inhibitory PAS domain protein gene expression by hypoxia-inducible factor 1 (HIF-1): a negative feedback regulatory circuit in HIF-1-mediated signaling in hypoxic cells","volume":"282","author":"Makino","year":"2007","journal-title":"J Biol Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2015.06.017","article-title":"The action of HIF-3\u03b1 variants on HIF-2\u03b1-HIF-1\u03b2 heterodimer formation is directly probed in live cells","volume":"336","author":"Kim","year":"2015","journal-title":"Exp Cell Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28577","article-title":"Down-regulation of TIMP2 by HIF-1\u03b1\/miR-210\/HIF-3\u03b1 regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma","volume":"64","author":"Kai","year":"2016","journal-title":"Hepatology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e23889","DOI":"10.1002\/jcla.23889","article-title":"Aberrant expression of HIF3A in plasma of patients with non-small cell lung cancer and its clinical significance","volume":"35","author":"Wei","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"B53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.cmet.2011.08.006","article-title":"The differential role of Hif1\u03b2\/Arnt and the hypoxic response in adipose function, fibrosis, and inflammation","volume":"14","author":"Lee","year":"2011","journal-title":"Cell Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2014.00032","article-title":"Hypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT) (HIF-1\u03b2): is it a rare exception","volume":"20","author":"Mandl","year":"2014","journal-title":"Mol Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.25.15117","article-title":"The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression","volume":"271","author":"Wood","year":"1996","journal-title":"Stud ARNT-deficient Cells J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e202201756","DOI":"10.26508\/lsa.202201756","article-title":"Multi-level interaction between HIF and AHR transcriptional pathways in kidney carcinoma","volume":"6","author":"Lafleur","year":"2023","journal-title":"Life Sci Alliance"},{"key":"B58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40360-022-00564-8","article-title":"Interaction between AhR and HIF-1 signaling pathways mediated by ARNT\/HIF-1\u03b2","volume":"23","author":"Zhang","year":"2022","journal-title":"BMC Pharmacol Toxicol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e70700","DOI":"10.7759\/cureus.70700","article-title":"Hypoxia-inducible factor 1-alpha (HIF-1\u03b1) and cancer: mechanisms of tumor hypoxia and therapeutic targeting","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010268","article-title":"The role of hypoxia-inducible factor post-translational modifications in regulating its localisation, stability, and activity","volume":"22","author":"Albanese","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1124\/mol.106.027029","article-title":"Hypoxia-inducible factor-1 (HIF-1)","volume":"70","author":"Ke","year":"2006","journal-title":"Mol Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2019.00004","article-title":"Hypoxia-modified cancer cell metabolism","volume":"7","author":"Al Tameemi","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.04.001","article-title":"HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity","volume":"11","author":"Zhang","year":"2007","journal-title":"Cancer Cell"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)31580-6","article-title":"Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1","volume":"269","author":"Semenza","year":"1994","journal-title":"J Biol Chem"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2012.969","article-title":"Expression of hypoxia-related glucose transporters GLUT1 and GLUT3 in benign, Malignant and non-neoplastic thyroid lesions","volume":"6","author":"J\u00f3\u017awiak","year":"2012","journal-title":"Mol Med Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1677\/joe.1.05599","article-title":"Induction of glucose transporter 1 expression through hypoxia-inducible factor 1alpha under hypoxic conditions in trophoblast-derived cells","volume":"183","author":"Hayashi","year":"2004","journal-title":"J Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010144200","article-title":"Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia","volume":"276","author":"Chen","year":"2001","journal-title":"J Biol Chem"},{"key":"B68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1113\/JP280572","article-title":"Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology","volume":"599","author":"Kierans","year":"2021","journal-title":"J Physiol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.2000.278.2.L407","article-title":"Hypoxia induces hexokinase II gene expression in human lung cell line A549","volume":"278","author":"Riddle","year":"2000","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.012","article-title":"HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption","volume":"3","author":"Papandreou","year":"2006","journal-title":"Cell Metab"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.04.001","article-title":"The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism","volume":"356","author":"Lu","year":"2015","journal-title":"Cancer Lett"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00210","article-title":"Exploring monocarboxylate transporter inhibition for cancer treatment","volume":"5","author":"Koltai","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-014-0129-1","article-title":"Acidic extracellular pH promotes epithelial mesenchymal transition in Lewis lung carcinoma model","volume":"14","author":"Suzuki","year":"2014","journal-title":"Cancer Cell Int"},{"key":"B74","first-page":"79","article-title":"Extracellular acidity as favouring factor of tumor progression and metastatic dissemination","volume":"34","author":"Calorini","year":"2012","journal-title":"Exp Oncol"},{"key":"B75","article-title":"Acidic extracellular microenvironment promotes the invasion and cathepsin B secretion of PC-3 cells","volume":"8","author":"Gao","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1038\/s41467-022-32521-8","article-title":"Lactate increases stemness of CD8\u2009+\u2009T cells to augment anti-tumor immunity","volume":"13","author":"Feng","year":"2022","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115703","article-title":"Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target","volume":"22","author":"Infantino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010050","article-title":"Hypoxia-inducible factor 1 and mitochondria: an intimate connection","volume":"13","author":"Huang","year":"2022","journal-title":"Biomolecules"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.4161\/cc.8.17.9544","article-title":"HIF-1 prevents the overproduction of mitochondrial ROS after cytokine stimulation through induction of PDK-1","volume":"8","author":"Kirito","year":"2009","journal-title":"Cell Cycle"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2006.033506","article-title":"Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia","volume":"91","author":"Guzy","year":"2006","journal-title":"Exp Physiol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2005.03.088","article-title":"A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1alpha","volume":"579","author":"Sanju\u00e1n-Pla","year":"2005","journal-title":"FEBS Lett"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12051075","article-title":"PGC-1\u03b1 Is a master regulator of mitochondrial lifecycle and ROS stress response","volume":"12","author":"Abu Shelbayeh","year":"2023","journal-title":"Antioxid (Basel)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6235641","article-title":"Redox homeostasis and cellular antioxidant systems: crucial players in cancer growth and therapy","volume":"2016","author":"Marengo","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15068","article-title":"Reactive oxygen species in cancer: Current findings and future directions","volume":"112","author":"Nakamura","year":"2021","journal-title":"Cancer Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00504-8","article-title":"Glutamine reliance in cell metabolism","volume":"52","author":"Yoo","year":"2020","journal-title":"Exp Mol Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav2588","article-title":"Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion","volume":"366","author":"Leone","year":"2019","journal-title":"Science"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.994672","article-title":"Glutamine metabolism in cancers: Targeting the oxidative homeostasis","volume":"12","author":"Gong","year":"2022","journal-title":"Front Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-015-1307-x","article-title":"Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate\/H(+) symporters","volume":"94","author":"Marchiq","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1038\/oncsis.2015.50","article-title":"Hypoxia and metabolic adaptation of cancer cells","volume":"5","author":"Eales","year":"2016","journal-title":"Oncogenesis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semcdb.2019.05.031","article-title":"The multifaceted contribution of \u03b1-ketoglutarate to tumor progression: An opportunity to exploit","volume":"98","author":"Abla","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/s41392-020-00326-0","article-title":"NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications","volume":"5","author":"Ju","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01179-17","article-title":"A critical role of glutamine and asparagine \u03b3-nitrogen in nucleotide biosynthesis in cancer cells hijacked by an oncogenic virus","volume":"8","author":"Zhu","year":"2017","journal-title":"mBio"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.110.084244","article-title":"Role of glutamine in cancer: therapeutic and imaging implications","volume":"52","author":"Rajagopalan","year":"2011","journal-title":"J Nucl Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.09.025","article-title":"Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport","volume":"56","author":"Yang","year":"2014","journal-title":"Mol Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3390\/biom10010135","article-title":"Modulation of mitochondrial metabolic reprogramming and oxidative stress to overcome chemoresistance in cancer","volume":"10","author":"Avolio","year":"2020","journal-title":"Biomolecules"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020195","article-title":"Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation","volume":"17","author":"Qannita","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810199105","article-title":"Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction","volume":"105","author":"Wise","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03039-y","article-title":"Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria","volume":"76","author":"Thomas","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B101","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41419-021-03505-1","article-title":"The crosstalk between HIFs and mitochondrial dysfunctions in cancer development","volume":"12","author":"Bao","year":"2021","journal-title":"Cell Death Dis"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e140100","DOI":"10.1172\/JCI140100","article-title":"Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer","volume":"131","author":"Edwards","year":"2021","journal-title":"J Clin Invest"},{"key":"B103","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-024-02994-0","article-title":"A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle","volume":"43","author":"Wang","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/cbin.70031","article-title":"Regulatory T cells in tumor microenvironment: therapeutic approaches and clinical implications","volume":"49","author":"Sureka","year":"2025","journal-title":"Cell Biol Int"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131859","article-title":"Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells","volume":"130","author":"Oh","year":"2020","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3796","article-title":"\u03b1-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming","volume":"18","author":"Liu","year":"2017","journal-title":"Nat Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.01.005","article-title":"Glutamine metabolism in cancer: understanding the heterogeneity","volume":"3","author":"Cluntun","year":"2017","journal-title":"Trends Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105131","article-title":"Lipid-mediated regulation of the cancer-immune crosstalk","volume":"161","author":"Ma","year":"2020","journal-title":"Pharmacol Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1021\/cbmi.4c00050","article-title":"Alteration of lipid metabolism in hypoxic cancer cells","volume":"3","author":"Gonzalez","year":"2024","journal-title":"Chem BioMed Imaging"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3058","article-title":"Hypoxia induces a lipogenic cancer cell phenotype via HIF1\u03b1-dependent and -independent pathways","volume":"6","author":"Valli","year":"2015","journal-title":"Oncotarget"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cells8030214","article-title":"Hypoxia-inducible factors and the regulation of lipid metabolism","volume":"8","author":"Mylonis","year":"2019","journal-title":"Cells"},{"key":"B112","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s42003-020-01367-5","article-title":"Fatty-acid-induced FABP5\/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells","volume":"3","author":"Seo","year":"2020","journal-title":"Commun Biol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.08.028","article-title":"HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression","volume":"8","author":"Huang","year":"2014","journal-title":"Cell Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2006.05.045","article-title":"Hypoxia-induced fatty acid transporter translocation increases fatty acid transport and contributes to lipid accumulation in the heart","volume":"580","author":"Chabowski","year":"2006","journal-title":"FEBS Lett"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/srep14752","article-title":"Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"5","author":"Nath","year":"2015","journal-title":"Sci Rep"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.08.056","article-title":"Fatty acid uptake and lipid storage induced by HIF-1\u03b1 contribute to cell growth and survival after hypoxia-reoxygenation","volume":"9","author":"Bensaad","year":"2014","journal-title":"Cell Rep"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0893-4","article-title":"FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis","volume":"38","author":"Cordero","year":"2019","journal-title":"Oncogene"},{"key":"B118","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1146\/annurev-biochem-061009-102430","article-title":"Lipid droplets and cellular lipid metabolism","volume":"81","author":"Walther","year":"2012","journal-title":"Annu Rev Biochem"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23081941","article-title":"Lipid droplets in cancer: guardians of fat in a stressful world","volume":"23","author":"Petan","year":"2018","journal-title":"Molecules"},{"key":"B120","article-title":"Lipid droplets and the management of cellular stress","volume":"92","author":"Jarc","year":"2019","journal-title":"Yale J Biol Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1104725","article-title":"Lipid droplets and polyunsaturated fatty acid trafficking: Balancing life and death","volume":"11","author":"Danielli","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41467-017-01965-8","article-title":"HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism","volume":"8","author":"Du","year":"2017","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-021-00791-3","article-title":"Downregulation of fatty acid oxidation by involvement of HIF-1\u03b1 and PPAR\u03b3 in human gastric adenocarcinoma and related clinical significance","volume":"77","author":"Ezzeddini","year":"2021","journal-title":"J Physiol Biochem"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcab035","article-title":"CPT1A and fatty acid \u03b2-oxidation are essential for tumor cell growth and survival in hormone receptor-positive breast cancer","volume":"3","author":"Jariwala","year":"2021","journal-title":"NAR Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1038\/s41467-024-50998-3","article-title":"Targeting fatty acid oxidation enhances response to HER2-targeted therapy","volume":"15","author":"Nandi","year":"2024","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113431","article-title":"CPT1A over-expression increases reactive oxygen species in the mitochondria and promotes antioxidant defenses in prostate cancer","volume":"12","author":"Joshi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143321","article-title":"Cancer-associated fibroblasts in the hypoxic tumor microenvironment","volume":"14","author":"Kim","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B128","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3892\/ijo.2022.5357","article-title":"\u2018Reverse Warburg effect\u2019 of cancer-associated fibroblasts (Review)","volume":"60","author":"Liang","year":"2022","journal-title":"Int J Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114802","article-title":"Understanding the relationship between cancer associated cachexia and hypoxia-inducible factor-1","volume":"163","author":"Muthamil","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2023.00137","article-title":"Transforming growth factor-\u03b2 signaling: from tumor microenvironment to anticancer therapy","volume":"4","author":"Chan","year":"2023","journal-title":"Explor Target Antitumor Ther"},{"key":"B131","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/cbin.12097","article-title":"Multifaceted TGF-\u03b2 signaling, a master regulator: From bench-to-bedside, intricacies, and complexities","volume":"48","author":"Ahuja","year":"2024","journal-title":"Cell Biol Int"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6075403","article-title":"Metabolic reprogramming of cancer associated fibroblasts: the slavery of stromal fibroblasts","volume":"2018","author":"Avagliano","year":"2018","journal-title":"BioMed Res Int"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The warburg effect: how does it benefit cancer cells","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.4161\/cc.8.23.10238","article-title":"The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma","volume":"8","author":"Pavlides","year":"2009","journal-title":"Cell Cycle"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69741","article-title":"Targeting lactate metabolism for cancer therapeutics","volume":"123","author":"Doherty","year":"2013","journal-title":"J Clin Invest"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113244","article-title":"Lactate in the tumor microenvironment: an essential molecule in cancer progression and treatment","volume":"12","author":"P\u00e9rez-Tom\u00e1s","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.688485","article-title":"Lactate is a metabolic mediator that shapes immune cell fate and function","volume":"12","author":"Caslin","year":"2021","journal-title":"Front Physiol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1795","article-title":"Tumor-derived lactic acid modulates dendritic cell activation and antigen expression","volume":"107","author":"Gottfried","year":"2006","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1038\/nature13490","article-title":"Functional polarization of tumour-associated macrophages by tumour-derived lactic acid","volume":"513","author":"Colegio","year":"2014","journal-title":"Nature"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102969","article-title":"Cancer-associated fibroblasts: accomplices in the tumor immune evasion","volume":"12","author":"Hilmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1113378","article-title":"CAFs orchestrates tumor immune microenvironment-A new target in cancer therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B145","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"B146","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","article-title":"Cancer associated fibroblasts in cancer development and therapy","volume":"18","author":"Jia","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143466","article-title":"Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy","volume":"13","author":"Belhabib","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B148","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-65768-0_14","article-title":"Metabolic relationship between cancer-associated fibroblasts and cancer cells","volume-title":"The heterogeneity of cancer metabolism","author":"Sazeides","year":"2021"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.12.011","article-title":"Tumor hypoxia: From basic knowledge to therapeutic implications","volume":"88","author":"Liao","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202702","article-title":"Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells","volume":"191","author":"Husain","year":"2013","journal-title":"J Immunol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41392-021-00598-0","article-title":"Lactate-avid regulatory T cells: metabolic plasticity controls immunosuppression in tumour microenvironment","volume":"6","author":"Multhoff","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metab"},{"key":"B154","doi-asserted-by":"publisher","first-page":"e2250258","DOI":"10.1002\/eji.202250258","article-title":"Acidity-mediated induction of FoxP3+ regulatory T cells","volume":"53","author":"Rao","year":"2023","journal-title":"Eur J Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e2350511","DOI":"10.1002\/eji.202350511","article-title":"Acidity promotes the differentiation of immunosuppressive regulatory T cells","volume":"53","author":"Tuomela","year":"2023","journal-title":"Eur J Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0111","article-title":"Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer","volume":"8","author":"Yang","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","article-title":"The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia","volume":"14","author":"Ding","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"47","DOI":"10.14216\/kjco.24322","article-title":"Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy","volume":"21","author":"Zaheer","year":"2025","journal-title":"Korean J Clin Oncol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"e150846","DOI":"10.1172\/JCI150846","article-title":"Targeting HIF-1\u03b1 abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues","volume":"132","author":"Bailey","year":"2022","journal-title":"J Clin Invest"},{"key":"B161","doi-asserted-by":"publisher","first-page":"e1056442","DOI":"10.1080\/2162402X.2015.1056442","article-title":"Hypoxia induces macrophage polarization and re-education toward an M2 phenotype in U87 and U251 glioblastoma models","volume":"5","author":"Leblond","year":"2015","journal-title":"Oncoimmunology"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1856","article-title":"Tumor hypoxia enhances Non-Small Cell Lung Cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling","volume":"5","author":"Zhang","year":"2014","journal-title":"Oncotarget"},{"key":"B163","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3892\/ijo.2023.5518","article-title":"Effects of glycolysis on the polarization and function of tumor-associated macrophages (Review)","volume":"62","author":"Cao","year":"2023","journal-title":"Int J Oncol"},{"key":"B164","article-title":"Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer","volume":"62","author":"Leek","year":"2002","journal-title":"Cancer Res"},{"key":"B165","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz","year":"2015","journal-title":"Hypoxia (Auckl)"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063313","article-title":"A molecular perspective on HIF-1\u03b1 and angiogenic stimulator networks and their role in solid tumors: an update","volume":"25","author":"Magar","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/549412","article-title":"Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies","volume":"2015","author":"Zimna","year":"2015","journal-title":"BioMed Res Int"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911423654","article-title":"Hypoxia-induced angiogenesis: good and evil","volume":"2","author":"Krock","year":"2011","journal-title":"Genes Cancer"},{"key":"B170","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-025-00779-x","article-title":"Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies","volume":"13","author":"Liu","year":"2025","journal-title":"biomark Res"},{"key":"B171","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1089\/ars.2025.1022","article-title":"Hypoxia-induced changes in endothelial cell phenotype and function","volume":"43","author":"T\u00f3th","year":"2025","journal-title":"Antioxid Redox Signal"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3390\/biom11070982","article-title":"Endothelial dysfunction driven by hypoxia-the influence of oxygen deficiency on NO bioavailability","volume":"11","author":"Janaszak-Jasiecka","year":"2021","journal-title":"Biomolecules"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.06.037","article-title":"Role of PFKFB3-driven glycolysis in vessel sprouting","volume":"154","author":"De Bock","year":"2013","journal-title":"Cell"},{"key":"B174","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.cmet.2020.03.009","article-title":"Single-cell RNA sequencing maps endothelial metabolic plasticity in pathological angiogenesis","volume":"31","author":"Rohlenova","year":"2020","journal-title":"Cell Metab"},{"key":"B175","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12967-024-04872-x","article-title":"Hypoxia-induced P4HA1 overexpression promotes post-ischemic angiogenesis by enhancing endothelial glycolysis through downregulating FBP1","volume":"22","author":"Xu","year":"2024","journal-title":"J Transl Med"},{"key":"B176","doi-asserted-by":"publisher","first-page":"e33418","DOI":"10.1371\/journal.pone.0033418","article-title":"Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis","volume":"7","author":"Sonveaux","year":"2012","journal-title":"PLoS One"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2006.00127.x","article-title":"Lactate stimulates endothelial cell migration","volume":"14","author":"Beckert","year":"2006","journal-title":"Wound Repair Regen"},{"key":"B178","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41388-024-03228-5","article-title":"The influence of endothelial metabolic reprogramming on the tumor microenvironment","volume":"44","author":"Kane","year":"2025","journal-title":"Oncogene"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.02.010","article-title":"Reengineering the tumor vasculature: improving drug delivery and efficacy","volume":"4","author":"Stylianopoulos","year":"2018","journal-title":"Trends Cancer"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01330-z","article-title":"Vascular normalisation as the stepping stone into tumour microenvironment transformation","volume":"125","author":"Magnussen","year":"2021","journal-title":"Br J Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00211","article-title":"Vascular permeability and drug delivery in cancers","volume":"3","author":"Azzi","year":"2013","journal-title":"Front Oncol"},{"key":"B182","article-title":"Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy","volume":"50","author":"Boucher","year":"1990","journal-title":"Cancer Res"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.13-S3-21","article-title":"Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis","volume":"13","author":"Vaupel","year":"2008","journal-title":"Oncologist"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189137","article-title":"The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions","volume":"1879","author":"Zhang","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.09.011","article-title":"Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds","volume":"80","author":"Ma","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041316","article-title":"Downstream targets of VHL\/HIF-\u03b1 Signaling in renal clear cell carcinoma progression: mechanisms and therapeutic relevance","volume":"15","author":"Mazumder","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A small-molecule antagonist of HIF2\u03b1 Is efficacious in preclinical models of renal cell carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 Antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04456-7","article-title":"Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma","volume":"165","author":"Strowd","year":"2023","journal-title":"J Neurooncol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von hippel-lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"B192","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(24)00649-1","article-title":"Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study","volume":"26","author":"Choueiri","year":"2025","journal-title":"Lancet Oncol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251317846","article-title":"Belzutifan for the treatment of renal cell carcinoma","volume":"17","author":"Wu","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1054","article-title":"FDA approval summary: belzutifan for von hippel-lindau disease-associated tumors","volume":"28","author":"Fallah","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0283","article-title":"LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma","volume":"19","author":"Choueiri","year":"2023","journal-title":"Future Oncol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-293","article-title":"Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition","volume":"12","author":"Chintala","year":"2012","journal-title":"BMC Cancer"},{"key":"B197","doi-asserted-by":"publisher","first-page":"e0188438","DOI":"10.1371\/journal.pone.0188438","article-title":"Restoration of the prolyl-hydroxylase domain protein-3 oxygen-sensing mechanism is responsible for regulation of HIF2\u03b1 expression and induction of sensitivity of myeloma cells to hypoxia-mediated apoptosis","volume":"12","author":"Gastelum","year":"2017","journal-title":"PLoS One"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.70","article-title":"Rapid degradation of hypoxia-inducible factor-1alpha by KRH102053, a new activator of prolyl hydroxylase 2","volume":"154","author":"Choi","year":"2008","journal-title":"Br J Pharmacol"},{"key":"B199","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ijc.22442","article-title":"Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model","volume":"120","author":"Lang","year":"2007","journal-title":"Int J Cancer"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1002\/lary.21724","article-title":"Efficacy and comparative effectiveness of sirolimus as an anticancer drug","volume":"121","author":"Hu","year":"2011","journal-title":"Laryngoscope"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.4161\/cc.5.21.3409","article-title":"Effects of histone deacetylase inhibitors on HIF-1","volume":"5","author":"Liang","year":"2006","journal-title":"Cell Cycle"},{"key":"B202","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4196\/kjpp.2024.28.1.83","article-title":"ACY-241, a histone deacetylase 6 inhibitor, suppresses the epithelial-mesenchymal transition in lung cancer cells by downregulating hypoxia-inducible factor-1 alpha","volume":"28","author":"Park","year":"2024","journal-title":"Korean J Physiol Pharmacol"},{"key":"B203","doi-asserted-by":"publisher","first-page":"e106224","DOI":"10.1371\/journal.pone.0106224","article-title":"The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition","volume":"9","author":"Hutt","year":"2014","journal-title":"PLoS One"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.11.015","article-title":"Targeting bromodomain and extraterminal proteins in breast cancer","volume":"129","author":"Sahni","year":"2018","journal-title":"Pharmacol Res"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.184","article-title":"The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer","volume":"36","author":"da Motta","year":"2017","journal-title":"Oncogene"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M600456200","article-title":"Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha","volume":"281","author":"Fath","year":"2006","journal-title":"J Biol Chem"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18125","article-title":"Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"B208","doi-asserted-by":"publisher","first-page":"FSO372","DOI":"10.4155\/fsoa-2018-0115","article-title":"Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy","volume":"5","author":"Alqahtani","year":"2019","journal-title":"Future Sci OA"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040634","article-title":"Anticancer therapy with HDAC inhibitors: mechanism-based combination strategies and future perspectives","volume":"13","author":"Jenke","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.3390\/ph15060667","article-title":"HDAC inhibitors for the therapy of triple negative breast cancer","volume":"15","author":"Maccallini","year":"2022","journal-title":"Pharm (Basel)"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.10.153","article-title":"RNA interference for HIF-1alpha inhibits its downstream signalling and affects cellular proliferation","volume":"312","author":"H\u00e4nze","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2692","article-title":"Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo","volume":"13","author":"Gillespie","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2009.66","article-title":"Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis","volume":"17","author":"Xu","year":"2010","journal-title":"Cancer Gene Ther"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700871","article-title":"Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers","volume":"13","author":"Mizuno","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3892\/or.2018.6667","article-title":"CRISPR\/Cas9-mediated hypoxia inducible factor-1\u03b1 knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma","volume":"40","author":"Liu","year":"2018","journal-title":"Oncol Rep"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0510","article-title":"A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth","volume":"7","author":"Greenberger","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.10.002","article-title":"Hypoxia signaling: Challenges and opportunities for cancer therapy","volume":"85","author":"Ivan","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1185","article-title":"Allosteric inhibition of hypoxia inducible factor-2 with small molecules","volume":"9","author":"Scheuermann","year":"2013","journal-title":"Nat Chem Biol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13619-015-0015-x","article-title":"Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles","volume":"4","author":"Fontaine","year":"2015","journal-title":"Cell Regen"},{"key":"B220","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.tibs.2025.06.005","article-title":"The HIF axes in cancer: angiogenesis, metabolism, and immune-modulation","volume":"50","author":"Acu\u00f1a-Pilarte","year":"2025","journal-title":"Trends Biochem Sci"},{"key":"B221","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm (2020)"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00682-7","article-title":"Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer","volume":"30","author":"Zhang","year":"2025","journal-title":"Cell Mol Biol Lett"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"B224","doi-asserted-by":"publisher","first-page":"e159473","DOI":"10.1172\/JCI159473","article-title":"Cross-talk between HIF and PD-1\/PD-L1 pathways in carcinogenesis and therapy","volume":"132","author":"Shurin","year":"2022","journal-title":"J Clin Invest"},{"key":"B225","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2022.01.027","article-title":"HIF-1\u03b1 inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer","volume":"531","author":"Luo","year":"2022","journal-title":"Cancer Lett"},{"key":"B226","doi-asserted-by":"publisher","first-page":"e156774","DOI":"10.1172\/JCI156774","article-title":"HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy","volume":"132","author":"Salman","year":"2022","journal-title":"J Clin Invest"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2163","article-title":"Targeting hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab","volume":"5","author":"Falchook","year":"2014","journal-title":"Oncotarget"},{"key":"B228","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3892\/ol.2021.12900","article-title":"Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1\u03b1\/TGF-\u03b1 expression","volume":"22","author":"Nishii","year":"2021","journal-title":"Oncol Lett"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3390\/cells9122598","article-title":"Hypoxia dictates metabolic rewiring of tumors: implications for chemoresistance","volume":"9","author":"Belisario","year":"2020","journal-title":"Cells"},{"key":"B230","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40170-025-00392-4","article-title":"Lactate dehydrogenase A-coupled NAD+ regeneration is critical for acute myeloid leukemia cell survival","volume":"13","author":"Erdem","year":"2025","journal-title":"Cancer Metab"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15266","article-title":"HIF1\/2\u03b1 mediates hypoxia-induced LDHA expression in human pancreatic cancer cells","volume":"8","author":"Cui","year":"2017","journal-title":"Oncotarget"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2012.08748.x","article-title":"Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma","volume":"279","author":"Sheng","year":"2012","journal-title":"FEBS J"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1275000","article-title":"Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases","volume":"14","author":"Han","year":"2023","journal-title":"Front Pharmacol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2016.09.009","article-title":"FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells","volume":"161","author":"Rellinger","year":"2017","journal-title":"Surgery"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2016.04.029","article-title":"Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma","volume":"81","author":"Gao","year":"2016","journal-title":"BioMed Pharmacother"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1275000","article-title":"Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases","volume":"14","author":"Han","year":"2023","journal-title":"Front Pharmacol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02082-x","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B238","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pbiomolbio.2025.05.003","article-title":"Advances in the mechanisms of HIF-1\u03b1-enhanced tumor glycolysis and its relation to dedifferentiation","volume":"197","author":"Zeng","year":"2025","journal-title":"Prog Biophys Mol Biol"},{"key":"B239","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2006.10.020","article-title":"A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth","volume":"11","author":"Bonnet","year":"2007","journal-title":"Cancer Cell"},{"key":"B240","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ygyno.2008.01.038","article-title":"Dichloroacetate induces apoptosis in endometrial cancer cells","volume":"109","author":"Wong","year":"2008","journal-title":"Gynecol Oncol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605701","article-title":"Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells","volume":"102","author":"Madhok","year":"2010","journal-title":"Br J Cancer"},{"key":"B242","doi-asserted-by":"publisher","first-page":"31ra34","DOI":"10.1126\/scitranslmed.3000677","article-title":"Metabolic modulation of glioblastoma with dichloroacetate","volume":"2","author":"Michelakis","year":"2010","journal-title":"Sci Transl Med"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0047-4","article-title":"Phase 1 trial of dichloroacetate (DCA) in adults with recurrent Malignant brain tumors","volume":"32","author":"Dunbar","year":"2014","journal-title":"Invest New Drugs"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10694","article-title":"Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S11795","article-title":"In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds","volume":"2","author":"Olszewski","year":"2010","journal-title":"Clin Pharmacol"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3128-y","article-title":"Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells","volume":"147","author":"Haugrud","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01235-5","article-title":"Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma","volume":"40","author":"Powell","year":"2022","journal-title":"Invest New Drugs"},{"key":"B248","doi-asserted-by":"publisher","first-page":"e70120","DOI":"10.1002\/mco2.70120","article-title":"Glutamine metabolism: molecular regulation, biological functions, and diseases","volume":"6","author":"Kumar","year":"2020","journal-title":"MedComm"},{"key":"B249","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-21-1204","article-title":"A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors","volume":"27","author":"Harding","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0061","article-title":"Telaglenastat plus everolimus in advanced renal cell carcinoma: A randomized, double-blinded, placebo-controlled, phase II ENTRATA trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3511","article-title":"Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial","volume":"8","author":"Tannir","year":"2022","journal-title":"JAMA Oncol"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104536","article-title":"A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer","volume":"10","author":"Gouda","year":"2025","journal-title":"ESMO Open"},{"key":"B253","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2021.39.15_suppl.3001","article-title":"First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients with molecularly selected advanced solid tumors","volume":"39","author":"Yap","year":"2021","journal-title":"J Clin Oncol"},{"key":"B254","doi-asserted-by":"publisher","first-page":"dmm050814","DOI":"10.1242\/dmm.050814","article-title":"Metabolic ripple effects - deciphering how lipid metabolism in cancer interfaces with the tumor microenvironment","volume":"17","author":"Jonker","year":"2024","journal-title":"Dis Model Mech"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.06.020","article-title":"Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression","volume":"2","author":"Ventura","year":"2015","journal-title":"EBioMedicine"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02567-z","article-title":"Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis","volume":"42","author":"Li","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2016.04.011","article-title":"Fasnall, a selective FASN inhibitor, shows potent anti-tumor activity in the MMTV-neu model of HER2(+) breast cancer","volume":"23","author":"Alwarawrah","year":"2016","journal-title":"Cell Chem Biol"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112447","article-title":"Deciphering fatty acid synthase inhibition-triggered metabolic flexibility in prostate cancer cells through untargeted metabolomics","volume":"9","author":"Oh","year":"2020","journal-title":"Cells"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32359","article-title":"Therapeutic efficacy of FASN inhibition in preclinical models of HCC","volume":"76","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"B260","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41392-022-01099-4","article-title":"Discovery of a mammalian FASN inhibitor against xenografts of non-small cell lung cancer and melanoma","volume":"7","author":"Cao","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1808834116","article-title":"Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer","volume":"116","author":"Zadra","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2019.1595308","article-title":"When fat goes down, prostate cancer is on the ropes","volume":"6","author":"Zadra","year":"2019","journal-title":"Mol Cell Oncol"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.355","article-title":"The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas","volume":"107","author":"Seguin","year":"2012","journal-title":"Br J Cancer"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1136","article-title":"The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas","volume":"13","author":"Agostini","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1471132","article-title":"Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy","volume":"27","author":"Schcolnik-Cabrera","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"B266","doi-asserted-by":"publisher","first-page":"e34671","DOI":"10.1097\/MD.0000000000034671","article-title":"Pharmacological effect and mechanism of orlistat in anti-tumor therapy: A review","volume":"102","author":"Hao","year":"2023","journal-title":"Med (Baltimore)"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2807","article-title":"Phase II investigation of TVB-2640 (Denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma","volume":"29","author":"Kelly","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.08.023","article-title":"A fatty acid synthase inhibitor shows new anticancer mechanisms","volume":"2","author":"Bueno","year":"2015","journal-title":"EBioMedicine"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.2174\/0929867322666151021111016","article-title":"Hypoxia activated prodrugs: factors influencing design and development","volume":"22","author":"Liang","year":"2015","journal-title":"Curr Med Chem"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2024.25.4.1121","article-title":"Regulation of hypoxia dependent reprogramming of cancer metabolism: role of HIF-1 and its potential therapeutic implications in leukemia","volume":"25","author":"Pandey","year":"2024","journal-title":"Asian Pac J Cancer Prev"},{"key":"B273","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1200\/JCO.2005.01.072","article-title":"Tirapazamine, Cisplatin, and Radiation versus Fluorouracil, Cisplatin, and Radiation in patients with locally advanced head and neck cancer: a randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02)","volume":"23","author":"Rischin","year":"2005","journal-title":"J Clin Oncol"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.4449","article-title":"Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group","volume":"28","author":"Rischin","year":"2010","journal-title":"J Clin Oncol"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.09.032","article-title":"A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"100","author":"Covens","year":"2006","journal-title":"Gynecol Oncol"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1351","article-title":"Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors","volume":"18","author":"von Pawel","year":"2000","journal-title":"J Clin Oncol"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.4265","article-title":"Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study","volume":"32","author":"DiSilvestro","year":"2014","journal-title":"J Clin Oncol"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0662","article-title":"Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003","volume":"26","author":"Mack","year":"2008","journal-title":"J Clin Oncol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0436","article-title":"Phase I study of tirapazamine plus cisplatin\/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study","volume":"10","author":"Le","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S304275","article-title":"Phase I trial on arterial embolization with hypoxia activated tirapazamine for unresectable hepatocellular carcinoma","volume":"8","author":"Abi-Jaoudeh","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.118455","article-title":"Phase I\/II study of the hypoxia-activated prodrug PR104 in refractory\/relapsed acute myeloid leukemia and acute lymphoblastic leukemia","volume":"100","author":"Konopleva","year":"2015","journal-title":"Haematologica"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-432","article-title":"A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients","volume":"11","author":"McKeage","year":"2011","journal-title":"BMC Cancer"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30381-9","article-title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406\/SARC021): an international, multicentre, open-label, randomised phase 3 trial","volume":"18","author":"Tap","year":"2017","journal-title":"Lancet Oncol"},{"key":"B284","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2016.34.15_suppl.4007","article-title":"MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC)","volume":"34","author":"Van Cutsem","year":"2016","journal-title":"J Clin Oncol"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0483","article-title":"A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced Malignancies","volume":"14","author":"Papadopoulos","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2021.04.004","article-title":"Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor","volume":"28","author":"Skwarska","year":"2021","journal-title":"Cell Chem Biol"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2021.08.016","article-title":"Hypoxia-activated KDAC inhibitor: Taking a breath from untargeted therapy","volume":"28","author":"Staudt","year":"2021","journal-title":"Cell Chem Biol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae038","article-title":"Introducing urea into tirapazamine derivatives to enhance anticancer therapy","volume":"11","author":"Xu","year":"2024","journal-title":"Natl Sci Rev"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1021\/jm020367","article-title":"Structure-activity relationships of 1, 2, 4-benzotriazine 1, 4-dioxides as hypoxia-selective analogues of tirapazamine","volume":"46","author":"Hay","year":"2003","journal-title":"J Med Chem"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.12.2889","article-title":"Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia","volume":"9","author":"Denny","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0478","article-title":"Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104","volume":"13","author":"Patterson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4023","article-title":"DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity","volume":"69","author":"Singleton","year":"2009","journal-title":"Cancer Res"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2013.00263","article-title":"The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104","volume":"3","author":"Foehrenbacher","year":"2013","journal-title":"Front Oncol"},{"key":"B294","doi-asserted-by":"publisher","first-page":"e23108","DOI":"10.1371\/journal.pone.0023108","article-title":"Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104","volume":"6","author":"Benito","year":"2011","journal-title":"PLoS One"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1671-3","article-title":"PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma","volume":"68","author":"Abou-Alfa","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.7504","article-title":"Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer","volume":"33","author":"Borad","year":"2015","journal-title":"J Clin Oncol"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2920-7","article-title":"Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs","volume":"77","author":"Phillips","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1564","article-title":"AQ4N: a new approach to hypoxia-activated cancer chemotherapy","volume":"83","author":"Patterson","year":"2000","journal-title":"Br J Cancer"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4020","article-title":"Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study","volume":"14","author":"Albertella","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.2429.2429","article-title":"Banoxantrone (AQ4N), a tissue targeted prodrug: results of a phase 1 study in lymphomas","volume":"108","author":"Furman","year":"2006","journal-title":"Blood"},{"key":"B301","unstructured":"Novacea, Inc. to discontinue cancer drug trial\n          \n          \n          2008"},{"key":"B302","unstructured":"Banoxantrone: Phase II discontinued\n          \n          \n          2008"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040847","article-title":"Improving tirapazamine (TPZ) to target and eradicate hypoxia tumors by gold nanoparticle carriers","volume":"14","author":"Ajnai","year":"2022","journal-title":"Pharmaceutics"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.06.026","article-title":"Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma","volume":"372","author":"Hao","year":"2024","journal-title":"J Control Release"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2023.12.149","article-title":"A two-stage exacerbated hypoxia nanoengineering strategy induced amplifying activation of tirapazamine for microwave hyperthermia-chemotherapy of breast cancer","volume":"659","author":"Zhao","year":"2024","journal-title":"J Colloid Interface Sci"},{"key":"B306","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12951-023-02203-8","article-title":"TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer","volume":"21","author":"Wang","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"B307","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40537-024-00945-2","article-title":"Hypoxia within tumor microenvironment characterizes distinct genomic patterns and aids molecular subtyping for guiding individualized immunotherapy","volume":"11","author":"Shi","year":"2024","journal-title":"J Big Data"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2025.100764","article-title":"Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures","volume":"5","author":"Di Giovannantonio","year":"2025","journal-title":"Cell Genom"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R117.799973","article-title":"Oxygen availability and metabolic reprogramming in cancer","volume":"292","author":"Xie","year":"2017","journal-title":"J Biol Chem"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.3390\/cells14141057","article-title":"Influence of hypoxia on tumor heterogeneity, DNA repair, and cancer therapy: from molecular insights to therapeutic strategies","volume":"14","author":"Kunachowicz","year":"2025","journal-title":"Cells"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v16.i12.1371","article-title":"Targeting hypoxia and angiogenesis in hepatocellular carcinoma: New insights and therapeutic strategies","volume":"16","author":"Du","year":"2024","journal-title":"World J Hepatol"},{"key":"B312","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1002\/mco2.203","article-title":"Hypoxia signaling in cancer: Implications for therapeutic interventions","volume":"4","author":"Zhuang","year":"2023","journal-title":"MedComm (2020)"},{"key":"B313","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13046-023-02724-y","article-title":"Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance","volume":"42","author":"Kao","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B314","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S140462","article-title":"Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment","volume":"13","author":"Graham","year":"2018","journal-title":"Int J Nanomed"},{"key":"B315","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.961637","article-title":"Role of hypoxia in the tumor microenvironment and targeted therapy","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B316","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-025-01722-1","article-title":"Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance","volume":"18","author":"Cheng","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B317","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12943-024-02113-9","article-title":"Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective","volume":"23","author":"Xiao","year":"2024","journal-title":"Mol Cancer"},{"key":"B318","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2024.100408","article-title":"Advancements in pathology: Digital transformation, precision medicine, and beyond","volume":"16","author":"Ahuja","year":"2024","journal-title":"J Pathol Inform"},{"key":"B319","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1561388","article-title":"Single-cell and spatial transcriptomic insights into glioma cellular heterogeneity and metabolic adaptations","volume":"16","author":"Fu","year":"2025","journal-title":"Front Immunol"},{"key":"B320","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154989","article-title":"ChatGPT as an aid for pathological diagnosis of cancer","volume":"253","author":"Malik","year":"2024","journal-title":"Pathol Res Pract"},{"key":"B321","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146679","article-title":"Use of radiomics in characterizing tumor hypoxia","volume":"26","author":"Huang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2022.04.004","article-title":"18F]FDG-PET\/CT radiomics and artificial intelligence in lung cancer: technical aspects and potential clinical applications","volume":"52","author":"Manafi-Farid","year":"2022","journal-title":"Semin Nucl Med"},{"key":"B323","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.29450","article-title":"The future of MRI in radiation therapy: Challenges and opportunities for the MR community","volume":"88","author":"Goodburn","year":"2022","journal-title":"Magn Reson Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1771365\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:32:44Z","timestamp":1774935164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1771365\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":323,"alternative-id":["10.3389\/fonc.2026.1771365"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1771365","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1771365"}}